Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dendreon’s Therapeutic Vaccine Provenge Gets “Complete Response” From FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is requesting additional clinical data to support the efficacy of Dendreon’s BLA.

You may also be interested in...



PDUFA Cliffhanger: Will FDA End The Provenge Regulatory Saga?

FDA approval of Provenge for prostate cancer could come May 1, opening the door for the launch of the first cancer immunotherapy.

PDUFA Cliffhanger: Will FDA End The Provenge Regulatory Saga?

FDA approval of Provenge for prostate cancer could come May 1, opening the door for the launch of the first cancer immunotherapy.

Chart: Oncology: The Race Is On In HRPC; Sponsors Of Niche Oncologics Struggle

Sanofi-Aventis expects to complete a rolling NDA submission for its "home grown" novel taxoid Jevtana (cabazitaxel) by the end of the first quarter, Sanofi-Aventis Global Operations President Hanspeter Spek told a Feb. 10 earning call.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066148

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel